Cobitolimod for moderate-to-severe, left-sided ulcerative colitis (CONDUCT): a phase 2b randomised, double-blind, placebo-controlled, dose-ranging induction trial

RCT (n=213) found that 2 topical administrations via rectal enema of cobitolimod 250mg (Toll-like receptor 9 activator) improved clinical remission rate at week 6 vs, placebo (21% vs 7%, OR 3.8, p=0.025). Adverse effects were found in 43% & 48%,respectively.

Source:

Lancet Gastroenterology and Hepatology